Dexmedetomidine modulates neuroinflammation and improves outcome via alpha2-adrenergic receptor signaling after rat spinal cord injury. by Gao, Jiandong et al.
UCSF
UC San Francisco Previously Published Works
Title
Dexmedetomidine modulates neuroinflammation and improves outcome via alpha2-
adrenergic receptor signaling after rat spinal cord injury.
Permalink
https://escholarship.org/uc/item/80r3p1tg
Journal
British journal of anaesthesia, 123(6)
ISSN
0007-0912
Authors
Gao, Jiandong
Sun, Zhihua
Xiao, Zhaoyang
et al.
Publication Date
2019-12-01
DOI
10.1016/j.bja.2019.08.026
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Dexmedetomidine Modulates Neuroinflammation and Improves
Outcome via 2 Adrenoceptor Signaling Following Rat Spinal Cord
Injury
Jiandong Gao1,5,, Zhihua Sun1,6,, Zhaoyang Xiao1,7, Qihang Du1,8, Xinhuan Niu1,8,
Gongming Wang1,8, Yu-Wen Chang1,2, Yongtao Sun1,9, Wei Sun1,8, Amity Lin1,2,
Jacqueline C. Bresnahan2,3,4, Mervyn Maze1, Michael S. Beattie2,3,4,# Jonathan Z. Pan1,2,#
1. Dept. of Anesthesia and Perioperative Care, University of California, San 
Francisco, CA, USA  
2. Brain and Spinal Injury Center (BASIC), University of California, San 
Francisco, CA, USA
3. Dept. of Neurological Surgery, University of California, San Francisco, CA,
USA
4. Weill Institutes for Neuroscience, University of California, San Francisco, 
CA, USA
5. Dept. of Anesthesiology, Beijing Chao-Yang Hospital, Capital Medical 
University, Beijing, China 100020
6. Dept. of Anesthesiology, Xiangya Hospital, Central South University, 
Changsha, Hunan, China 410008
7. Dept. of Emergency Intensive Care Unit, The Second Affiliated Hospital, 
Dalian Medical University, Dalian, Liaoning, China 116023
8. Dept. of Anesthesiology, Shandong Provincial Hospital, Shandong 
University, Jinan, Shandong, China 250021
9. Dept. of Anesthesiology, Qianfoshan Hospital, Shandong University, 
Jinan, Shandong, China 250014
Running title: Dexmedetomidine improves recovery after SCI
 Both authors contributed equally to this manuscript
# Corresponding authors: 
Michael Beattie, PhD. 
Professor and Director of Research
Brain and Spinal Injury Center
Weill Institute for Neurosciences
Department of Neurological Surgery
University of California, San Francisco
Michael.Beattie@ucsf.edu
Jonathan Pan, PhD., MD.
Assistant Professor
Department of Anesthesia and Perioperative Care
Brain and Spinal Injury Center
1
University of California, San Francisco
Jonathan.Pan@ucsf.edu
2
Abstract
Background: Spinal cord injury (SCI) induces inflammatory responses that include 
release of cytokines, recruitment and activation of macrophages and microglia. 
Neuroinflammation at the injury site contributes to secondary tissue damage and 
permanent locomotor dysfunction. Dexmedetomidine (DEX), a highly selective 2 
adrenergic receptor (AR) agonist, is anti-inflammatory and neuroprotective in both 
preclinical and clinical trials. We investigated the effect of DEX on microglia response,
histological and behavioural outcomes in a rat model of cervical SCI.
Methods: Animals underwent unilateral (right) C5 spinal cord contusion (75 Kdyne) 
using infinite horizon (IH) device. Locomotor function, injury size, inflammatory 
responses were assessed. DEX’s effect was also studied in a microglial cell culture 
model.  
Results: DEX significantly improved ipsilateral upper limb motor dysfunction 
(grooming and paw placement; p<0.0001 and p=0.0012), decreased injury size 
(p<0.05), spared white matter (p<0.05) and reduced number of activated 
macrophages (p<0.05) at the injury site 4 weeks post-SCI. At 6- and 24-hours after 
injury, tissue RNA expression by Q-RT-PCR revealed significant down-regulation of 
pro-inflammatory markers (e.g. IL-1, TNF, IL-6, CD11b) and up-regulation of anti-
inflammatory and pro-resolving “M2” responses (e.g. IL-4, Arginase-1 and CD206) 
(p<0.05). In LPS-stimulated cultured microglia, DEX produced a similar inflammation-
modulatory effect as was seen in SCI. The benefits of DEX on these outcomes were 
mostly reversed by 2AR antagonist. 
Conclusion: DEX significantly improves behavioural outcomes and decreases tissue 
damage, which is associated with modulation of neuroinflammation and is mediated 
via 2AR signaling following SCI. 
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Introduction
Spinal cord injury (SCI) induces an inflammatory response that can lead to cell death, 
tissue damage and neurological dysfunction.1, 2 Post-SCI inflammation is a precursor 
to subsequent pathological changes, including cellular necrosis, apoptosis, gliosis and
demyelination.2, 3 Anti-inflammatory therapies are effective in reducing tissue damage
and promoting functional recovery.4-6 Depletion of haematogenous macrophages or 
deletion of resident microglia can improve axonal regeneration and outcome.7, 8 
Nonetheless, “primed” macrophages can also be pro-reparative and may improve 
outcome.9 This paradox may be due to the presence of several functional 
macrophage varieties ranging from the classically-activated (“M1”) to the 
alternatively-activated (“M2”) phenotypes; even though some have challenged this 
dynamic construct as being more evident in vitro than in vivo,10, 11 for the purposes of 
this report we will use that concept. Enhancement of M1 vs M2 responses is 
responsible for persistent neuroinflammation and impaired recovery.12 Therefore, 
treatments that modulate the balance from pro-inflammatory to 
anti-inflammatory/pro-resolving responses may be promising therapies for SCI.  
Dexmedetomidine (DEX), a highly selective 2 agonist, is often used as an 
anaesthetic adjunct for patient sedation and general anaesthesia in the intensive 
care unit (ICU) and operating room (OR) settings, respectively. Accumulating 
evidence has shown that DEX is protective in ischaemia-reperfusion injury (IRI) in a 
variety of organs, including the spinal cord, brain and heart.13-17 In a series of studies 
using spinal compression injury model (by clipping the cord), intrathecal delivery of 
DEX was shown to preserve neurones, reduce lipid peroxidation and inflammatory 
responses with equivalent effectiveness to methylprednisolone.18-20 More recent work 
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has demonstrated that DEX is neuroprotective, by reducing tissue oedema, 
inflammation and apoptosis and also improves locomotor function,21, 22 while 
modulating microglial polarization.23 However, DEX’s effect hasn’t been well studied 
in traumatic SCI using a more clinically-relevant treatment regimen. We utilized a 
well-established cervical spinal injury model (the most common site of SCI in humans)
24 and employed DEX intervention with repeated administrations post-SCI, which 
mimicks the continuous treatment to SCI patients beginning in the emergency room 
(ER) or Operating Room (OR) and continuing during the ICU stay. We tested the 
hypothesis that DEX improves outcomes and modulates neuroinflammatory 
responses in order to develop evidence to support the clinical use of 2 AR agonists, 
which may be a promising class of immunomodulatory agents for post-SCI care.  
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Methods
Animals
Long–Evans female rats (77 to 87 days old) that were housed in pairs with ad libitum 
access to food and water. All experiments were performed in accordance with 
National Institutes of Health guidelines and were approved by Institutional Animal 
Care and Use Committees at the University of California, San Francisco.
Spinal cord injury and animal care 
All surgical procedures were performed aseptically. Animals were administered 
cefazolin 50 mg kg-1 prior to surgery and for one day postoperatively. Animals were 
anaesthetised with 2% isoflurane and a dorsal midline incision was made. Connective 
tissue and muscle layers were dissected and a C5 laminectomy was performed.24, 25 
Unilateral (right) cervical contusion injury (75 Kdyne) was produced with an Infinite 
Horizon (IH) device with a modified 1.0-mm-diameter impounder. This produces an 
ipsilateral focal lesion with minimal contralateral spread. The surgical control group 
underwent all procedures without contusion. After injury, underlying muscle layers 
were sutured and skin incision closed with wound clips. Animals were placed in 
incubator at 37oC for the first day post-surgery and monitored for food and water 
intake. Animals were then returned to cages and daily checked for bladder function 
and wound healing for the first two-week following SCI. 
Animal drug treatment 
Following SCI, 25 g kg-1 of DEX (Henry Schein) or vehicle (Saline) was injected i.p. at 
0, 2, 4, 6h on day 0 and once daily from day 1 to day 5 post-injury. Yohimbine (Yoh, 
Sigma-Aldrich), an 2 AR antagonist at a dose of 10 g kg-1 was given i.p. 15 min 
before each DEX administration post-SCI for 5 days.  
Behavioural analyses
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Paw placement test. Paw placement assessments were performed as previously 
described.24, 26 Briefly, rats were placed in a clear plastic cylinder and their behaviours
were recorded. The number of times the rats placed its left, right, or both forepaws 
against the cylinder during weight-supported movements was counted. Frequency of 
contralateral (left) forepaw placement was calculated and used as an indicator for 
functional recovery on ipsilateral (right) side. Rats were tested before surgery, at 
2 day after SCI and then weekly thereafter for 4 weeks.
Grooming test. Grooming scores was used to evaluate recovery of forelimb range of 
motion.24, 26 Cool water was gently sprayed and applied to the rat’s head and back, 
and then the animal was placed in a clear plastic cylinder. Grooming activity was 
recorded and evaluated using a 6-point scoring scale as follows: 0: no contact with 
the forepaw to any part of the face or head; 1: contact of forepaw with the underside 
of the chin and/or mouth area; 2: contact of forepaw with the area between the nose 
and eyes, but not the eyes; 3: contact of forepaw with the eyes and the area between
eyes and the front of the ears, but not the ears; 4: contact of forepaw with the ears, 
but not the area of the head behind the ears; 5: contact of forepaw with the area of 
the head behind the ears. Animals were tested at 2, 7, 14, 21, and 28 days after 
injury.
Tissue processing
Animals were sacrificed for histology under deep anaesthesia (i.e. Ketamine) by 
transcardiac perfusion with 0.9% saline followed by 4% paraformaldehyde.24 Lengths 
of spinal cord (10 mm) centered around the lesion were removed and post-fixed 
overnight in 4% paraformaldehyde. Tissue was cryoprotected in 30% sucrose for 2 
days, then embedded in optimal cutting temperature (OCT) compound and sectioned 
20 μm horizontally.
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Histological analyses 
Eriochrome Cyanine (EC) staining. Slides were placed in alcohol:chloroform (1:1) for 1 
h, washed in 100% alcohol (2 × 1 min), air-dried at room temperature (RT), and 
stained in eriochrome cyanine (EC) solution for 20-30 min, and then washed in 
running tap-water.25 After differentiation with iron alum and borax-ferricyanide 
solution, slides were counterstained in 0.5% neutral red (NR) for 1-2 min at RT. 
Sections were then dehydrated in alcohol, cleared in xylene and cover-slipped with 
mounting medium.
Immunohistochemical staining. Fixed tissue section was blocked and permeabilised 
for 1 h with 10% normal donkey serum and 0.3% Triton X-100. Sections were then 
incubated overnight at RT with mouse monoclonal antibody for CD11b (1:300).27 After
washing with 2 ml of PBS, slides were incubated for 1 hour at RT with fluorescent 
(Alexa 594) donkey-anti-mouse secondary antibody (1:1000). Slides were briefly 
rinsed with 2 ml PBS and cover-slipped with Vectashield containing DAPI (4′,6-
diamidino-2-phenylindole). The stained spinal tissue sections were photographed 
using the BIOREVO fluorescence microscope BZ-9000 Generation II (Keyence). 
Fluorescence was measured using BZ-9000 Generation II analyser and analysed by 
NIH Image J. 
RNA analysis
Total cellular RNA was isolated and purified from a 5-mm segment of injured or 
uninjured spinal cord using Trizol (Invitrogen) followed by RNeasy (Qiagen) binding, 
and quantified by a NanoDrop Lite (Thermo Scientific). cDNA was prepared from a 
total of 2 g RNA by reverse transcription. The PCR reactions were performed using 
10 ng of cDNA, 50 nm of each primer (Table 1),28 and SYBR Green master mix in 20 μl
reactions. Levels of Q-RT-PCR product were measured using SYBR Green fluorescence
9
collected on an Agilent Mx3005P Real-Time PCR system. Standard curves were 
generated for each gene using a control cDNA dilution series. Melting point analyses 
were performed for each reaction to confirm single amplified products.
Lesion volume measurement 
A camera lucida drawing of the section with the largest extent of lesion (the lesion 
epicentre) was made outlining intact grey and white matter, and the lesion.24 Pixel 
counts from digitised drawings in Adobe Photoshop 5.5 (Adobe Systems Inc.) were 
used to determine the area of spared tissue for both hemi-cords at the lesion 
centre.24, 25 The percent sparing for the ipsilateral hemi-cord was determined by 
dividing the total spared ipsilateral tissue area, spared white matter tissue area, or 
spared grey matter tissue area, by the same measure from the contralateral hemi-
cord. Lesion size from rostral to caudal direction at selected locations (-960, -720, -
480, -240, 0 240, 480, 720 and 960m) was calculated using the ratio of ipsilateral 
injured and contralateral hemi-cord area.
Microglia culture
The murine microglial BV-2 cell line,29 developed by Dr Blasi (University of Perugia, 
Perugia, Italy), was generously provided by Dr. Van Eldik from the University of 
Kentucky. BV-2 cells were cultured in Dulbecco's Modified Eagle's Medium/F12 
supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, 100 μg/ml 
streptomycin and 2 mM L-Glutamine. The cells were grown in a 37°C incubator, with 
humidified 95% air, 5% CO2. For experiments, cells were exposed to different 
reagents, e.g. lipopolysaccharide (LPS, 100 ng/ml), DEX (1M), yohimbine (100M) or 
vehicle in serum-containing medium. Typically, the cells were first treated with LPS 
for 1 h, followed by 24 h of incubation with vehicle only, DEX only, yohimbine only or 
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yohimbine 5 min prior to DEX (pretreatment for 5min) plus DEX. The supernatant and 
the BV-2 cell lysate were collected at the end of the 24-h exposures.
Statistical analysis 
GraphPad Prism 8 was used for statistical analyses and graphs (GraphPad Software, 
La Jolla, CA). Data are expressed as means ± SEM. Two-way analysis of variance 
(ANOVA) with repeated measures was used for behavioural and histological outcome 
analyses. One-way ANOVA with post hoc test for three groups or unpaired t tests for 
two group analyses were also applied as indicated in figure legends. Statistical 
significance was defined at p ≤ 0.05, 0.01, 0.001 or 0.0001 levels. 
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Results
DEX improves long-term outcomes via 2 adrenoceptors
Animals with unilateral (right) C5 spinal cord injury (SCI) were assessed for right 
forelimb motor function using paw placement and grooming tests.24, 26 Both 
behavioural tests were significantly improved in the DEX-treated SCI group (termed 
“SD”) compared to vehicle controls (SCI) over 4 weeks (Figure 1A-1: p=0.0012 and 
Figure 1B-1: p<0.0001, two-way ANOVA with repeated measures). At the end of 4 
weeks after injury, the difference between SCI and SD groups are also statistically 
significant (Figure 1A-2: 80.113.24% vs 43.9119.43%, *** p<0.0001 and Figure 
1B-2: 3.630.74 vs 4.630.52, ** p<0.01; one-way ANOVA with Tukey’s test). To test
whether DEX’s effect is mediated via 2 AR, yohimbine (Yoh), an 2 antagonist, was 
given to the SCI rats 15 min before DEX administration (SDY). Yoh reversed the 
sedative effect of DEX (by observation). Both behavioural measures (paw placement 
and grooming tests) were attenuated with a statistically significant difference (SD vs 
SDY in Figure 1A-2: 43.9119.43% vs 68.837.83%, ** p<0.01 and in Figure 1B-2: 
4.630.52 vs 3.860.35, * p<0.05, one-way ANOVA with Tukey’s test). 
DEX reduces tissue damage and promotes white matter sparing
Four weeks post-SCI, tissue injury at the epicentre and equi-distant rostrocaudally (-
960, -720, -480, -240, 0, 240, 480, 720 and 960 m) was assessed using Eriochrome 
Cyanine (EC) staining (Figure 2). At the maximal injury section, DEX (SD) significantly 
reduced lesion volume, compared to SCI group (Figure 2A-1, 2A-2 and 2A-4; SCI vs 
SD: 40.387.18 vs 27.99.26, * p<0.05, one-way ANOVA with Tukey’s test). It was 
also noted that cavity area commonly seen in the centre of damaged rat spinal cord 
tissue was consistently decreased in SD group (by observation). Tissue protection 
seen in the SD group is likely due to sparing of white matter (Figure 2A-5, SCI vs SD: 
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34.389.44% vs 45.818.81%, * p<0.05 and Figure 2A-6, SCI vs SD: 45.1713.6% 
vs 65.727.05% ** p<0.01; one-way ANOVA with Tukey’s test). There was no 
significant difference in grey matter-sparing between SCI and SD groups (Figure 2A-
7). Yoh inhibited DEX’s effect and attenuated the amount of spared white matter 
(Figure 2A-6, SD vs SDY: 65.727.05% vs 52.345.41%, * p<0.05; one-way ANOVA 
with Tukey’s test). Tissue injury area diminishes away from epicentre in SCI group 
(Figure 2B). However, DEX significantly reduced injury area at all indicated locations 
(SCI vs SD, p<0.0001, two-way ANOVA with multiple comparisons); this tissue 
protection was significantly attenuated by Yoh (SD vs SDY, p<0.0001, two-way 
ANOVA with multiple comparisons).  
DEX modulates neuroinflammation at injury site post-SCI
We used anti-CD11b antibody to label microglial population and to further assess the 
degree of intraspinal neuroinflammatory response at the injury epicentre and from 
rostral to caudal direction. As can be seen in Figure 3, CD11b signals significantly 
diminished rostro-caudally from the epicentre in SCI rats. When all CD11b signals at 
different levels were aggregated, there was significant difference between SCI and 
SD groups (SCI vs SD: 27.425.49% vs 16.873.18%, * p<0.05; Student’s t-test). At 
individual sections across the injury site, we found the most significant differences 
were located in areas adjacent to epicentre ( 480 m, * p<0.05, Student’s t-test). 
We further analysed gene expression of multiple pro-inflammatory and anti-
inflammatory cytokines and markers using Q-RT-PCR (Figure 4). Elevation of classic 
pro-inflammatory cytokines post-SCI was significantly reduced at 6h and 24h in DEX-
treated group (SD) following SCI (Figure 4A: * p<0.05; ** p<0.01 and *** p<0.001; 
one-way ANOVA with Tukey’s test). The elevated expression of CD11b (marker for 
microglia) RNA after injury was also significantly decreased both at 6h and 24h 
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(Figure 4A: ** p<0.01 and * p<0.05; one-way ANOVA with Tukey’s test). We also 
examined the expression of cytokine and markers that are pro-resolving and 
reparative (“M2” responses) (Figure 4B). Expression of IL-4, Arginase-1 and CD206 
mRNA was significantly upregulated by DEX at both 6h and 24h, compared to SCI 
only (Figure 4B, SCI vs SD: * p<0.05 and ** p<0.01; one-way ANOVA with Tukey’s 
test). Yoh, 2 antagonist was able to reverse most of these gene responses, 
especially in “M2” responses (Figure 4B: SD vs SDY: * p<0.05 and ** p<0.01; one-
way ANOVA with Tukey’s test). 
DEX modulates microglial activity toward “M2” phenotype
Pro-inflammatory cytokines such as IL-1, TNF and IL-6 were all up-regulated in LPS-
treated microglia (Figure 5, Panel A); these upregulated cytokines were significantly 
suppressed by DEX (Panel A, LPS vs DEX: * p<0.05, ** p<0.01 and **** p<0.0001; 
one-way ANOVA with Tukey’s test). On the other hand, transcription of classic “M2” 
response-associated genes such as IL-4, Arginase-1 and CD206 were enhanced in 
DEX-treated cells (Panel B, LPS vs DEX; * p<0.05; **** p<0.0001; one-way ANOVA 
with Tukey’s test); such DEX-induced effects were prevented by Yoh, especially in 
“M2” responses (Panel A and B, DEX vs Yoh: * p<0.05 and *** p<0.001; one-way 
ANOVA with Tukey’s test). 
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Discussion
In this study, we assessed the effect of DEX, a highly selective 2 AR agonist, on 
tissue injury and behavioural outcome. DEX significantly improved functional 
recovery (paw placement and grooming tests) (Figure 1), reduced lesion size and 
spared spinal tissue, especially white matter (Figure 2) over 4 weeks following SCI. 
DEX inhibited activated microglia and promoted anti-inflammatory and pro-resolving 
gene expression profile at the injury site (Figure 3 and 4). In LPS-stimulated microglia,
DEX produces similar inflammation-modulatory effect, consistent with in vivo spinal 
injury (Figure 5). As a framework for considering how these findings can ultimately 
improve outcome in SCI patients, we will address how (i) 2 AR-signaling may be 
beneficial, (ii) how DEX may be changing the inflammatory milieu in the injured spinal
cord and (iii) whether DEX is the most appropriate pharmacon for this action.    
2 adrenergic-receptor signaling is beneficial
2 AR agonists, such as clonidine, have been clinically used in SCI patients, especially
in those with chronic injury, autonomic dysreflexia (AD) and sexual dysfunction.30 
Clonidine has also been shown to restore sensorimotor function, control autonomic 
dysfunction and minimise spasticity in cat SCI model, likely through its actions on the 
adrenergic system in spinal cord pathways.31 DEX, a more selective 2 agonist than 
clonidine, has been shown to be anti-inflammatory in animal models of neurological 
disorders, including SCI;14, 21, 32, 33 however, its precise effects in the setting of 
traumatic SCI and the underlying mechanism for clinical benefit are still not well 
understood. In this study, DEX was systemically delivered (intraperitoneal) 
immediately after injury and every 2 hours for 6 hours on the day of SCI and once 
daily thereafter for 5 days. This regimen allowed the acutely-injured animal to remain
in a sedated state for hours after injury, which reproduced the clinical scenario of 
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acute post-SCI management in the OR and ICU. We observed significant functional 
improvement as soon as 2 days post-SCI in SD group (Figure 1), which is likely due to 
the multiple doses administered during day 0, the day on which SCI occurred. At the 
injury epicentre, DEX reduced the lesion volume and spared white matter (Figure 2), 
although we did see a trend of increased grey matter preservation that was also 
observed with neuronal staining with anti-NeuN antibody (data not shown). 
Interestingly, the cavity area at the injury epicentre also appeared smaller in SD 
group, most likely due to the spared white matter (observation only). These effects 
were largely negated by pretreatment with Yoh. The explanation for the less than 
complete reversal by Yoh may be due to non-2 AR-mediated actions of DEX that 
produce protection through imidazoline-receptor-mediated vagomimetic properties.34 
As the mechanism for the beneficial effects of DEX are further elucidated, we can 
expect the development of selective probes for these targets that are devoid of the 
cardiovascular adverse effects (bradycardia and hypotension) of 2 AR agonists. 
DEX modulates neuroinflammatory responses following SCI. 
The post-SCI inflammatory response aggravated the initial tissue injury and strategies
to minimize the response were effective in reducing tissue damage. However, if 
macrophages, the major effector cell in innate immune response, are alternatively 
activated to the “M2” phenotype, its function can become pro-resolving and 
reparative. Following SCI, both types of macrophages existed at the injury site, but 
was predominantly a pro-inflammatory response.
Since microglia/macrophages are known to express 2 ARs, DEX may directly impact 
their function in the injured spinal tissue.35 We selected anti-CD11b antibody to label 
and examine the local microglial response. CD11b positive cells were significantly 
reduced by DEX, especially in the area adjacent to injury epicentre (Figure 3). 
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Blockade of 2 AR signaling did not significantly change the effect of DEX on the 
number of CD11b positive cells, which suggests that 2 AR-mediated DEX effect may 
have had a greater impact on microglia function. By analysing the RNA expression in 
the spinal homogenate (Figure 4), we sought to determine which microglia phenotype
predominated in the microenvironment after DEX intervention. The SCI-mediated 
increased expression of each of the pro-inflammatory cytokines (IL-1, TNF and IL-6)
were significantly down-regulated in DEX-treated groups.  CD11b, the marker for 
activated microglia was also reduced by DEX (Figure 4A). In contrast, the anti-
inflammatory cytokine, IL-4, was promoted by DEX early after injury. DEX further 
enhanced the expression of “M2” phenotype markers such as Arginase-1 and CD206 
(Figure 4B). We speculate that this pro-resolving profile in the injured tissue following 
DEX may be responsible for the improved repair and recovery (Figure 1 and 2). Also, 
we employed microglial cells (BV-2 cell line) in which we established that DEX directly
influenced microglial phenotype (Figure 5). The up-regulation of pro-inflammatory 
cytokines (IL-1, TNF and IL-6) by LPS were all significantly suppressed in DEX-
treated cells. Furthermore, DEX also promoted a beneficial “M2” response as 
reflected by increased transcription of IL-4, Arginase-1 and CD206. These reactions 
are mainly mediated via 2 AR signaling. The findings in cell culture study are 
consistent with the transcriptional changes in the in vivo SCI studies. Our gene 
expression study corroborated findings from recent work,13, 23, 36 yet the underlying 
molecular mechanism via 2 AR signaling still needs to be further elucidated.      
Is 2 agonist a promising therapeutic immunomodulatory agent?
The autonomic nervous system plays a pivotal host defense response against injury 
and stressful stimuli.35 Stimulation of 2 ARs on immune cells regulates its 
development, function, and recruitment.37, 38 In previous studies, DEX has been shown
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to modulate macrophage/microglial activity.13, 22, 23, 36 In our study, we showed DEX’s 
effect on behavioural and histological outcomes, to be associated with favourable 
neuroinflammatory transcriptional profile following SCI. The DEX-induced changes of 
gene expression in the injured tissue suggests possible skewing of microglia towards 
“M2” phenotype. DEX can act directly on microglial 2 ARs on the cell surface and 
may regulate downstream pathways involved in microglial polarization.14, 23, 39 Further,
in our experiment, spinally-injured rats exhibited prominent vagomimetic symptoms 
(e.g. increased micturition and salivary secretion by observation) after DEX 
treatment, compared to vehicle controls. Activation of vagal response in these 
animals could potentially regulate systemic immune response by promoting 
cholinergic anti-inflammatory mechanism, which needs to be studied further.34, 40 
Being capable of modulating both neuroinflammation and systemic immune 
response, DEX and other selective 2-agonists are promising therapies that can be 
utilized beyond its current clinical indication in patients with neurotrauma (including 
SCI) to exploit its neuroprotective and immunomodulatory properties.
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Table 1: List of selected genes and PCR primers
GenBank ID Gene description Q-RT-PCR primers 
(forward/reverse)
Rat
NM_031512.2 IL-1 5'  TGCAGGCTTCGAGATGAACA  3'
5'  ACATGGGTCAGACAGCACGA  3'
NM_012675.3 TNF 5'  GAACTCCAGGCGGTGTCTGT  3'
5'  GCCACGAGCAGGAATGAGAA  3'
NM_012589.2 IL-6 5’  ATTCTGTCTCGAGCCCACCA  3’
5’  CTGAAGGGCAGATGGAGTTGA  3’
NM_201270.1 IL-4 5’  CCA GAC GTC CTT ACG GCA AC  3’
5’  GCA GAT GAG CTC GTT CTC CG  3’
NM_017134.3 Arginase-1 5’  CAT TTG GGT GGA TGC TCA CA  3’
5’  GAG CTG GTT GTC AGC GGA GT  3’
NM_001106123.2 CD206 5’  TGT CGG AGT CGC AGA TCA TG  3’
5’  GCA CCC CCA AAC ACA ATT TG  3’
NM_012711.1 CD11b 5’  CTG ATC AGA GCC CAG CCT GT  3’
5’  GCT GAA TTC CAT GGT TGC CT  3’ 
NM_017008.4 GAPDH 5’  ACC CAG CCC AGC AAG GAT AC  3’
5’  TCA GCA ACT GAG GGC CTC TC  3’
Mouse
NM_008361  IL-1 5’  GCAACTGTTCCTGAACTCAACT  3’
5’  ATCTTTTGGGGTCCGTCAACT  3’
NM_013693 TNF 5’  GTGATCGGTCCCCAAAGG  3’
5’  GGTGTGGGCCATAGAACTGATG  3’
NM_031168 IL-6 5’  GCCTCCTTGGGACTGATGCT  3’
24
5’  AGTCTCCTCTCCGGACTTGTG  3’
NM_021283.2 IL-4 5’  CTCGAATGTACCAGGAGCCA  3’
5’  TGTGGTGTTCTTCGTTGCTG  3’
NM_007482.2 Arginase-1 5’  GAACACGGCAGTGGCTTTAAC  3’
5’  TGCTTAGCTCTGTCTGCTTTGC  3’
NM_008625.1 CD206 5’  TCTTTGCCTTTCCCAGTCTCC 
 3’
5’  TGACACCCAGCGGAATTTC  3’
NM_008084 GAPDH 5’  CCAGCTCGTCCTGTAGACAA  3’
5’  GCCTTGACTGTGCCGTTGA  3’
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Figures
Figure 1. Dexmedetomidine (DEX) improves behavioural outcomes 4 weeks 
post-SCI.
Figure 1A.
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Figure 1B:
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Figure 2. DEX reduces damage and protects spinal tissue at injury site 
following SCI.
Figure 2A DEX reduces maximal injury areas and spares white mater at SCI epicentre.
          (1)  SCI                 (2) SD           (3) SDY
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Figure 2B. DEX decreases lesion size from rostral to caudal direction.
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Figure 3. Microglia activation is mitigated by DEX at injury site 28 days 
post-SCI 
(1) SCI          (2) SD
480m
(Rostral)
Epicentre
480m
(Caudal)
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Figure 4. DEX modulates neuro-inflammatory response post-SCI
Figure 4A. Expression of pro-inflammatory cytokines and marker in spinal tissue 6h 
and 24h following SCI
         (a) 6h        (b) 24h
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Figure 4B. Anti-inflammatory and pro-resolving M2 response at 6h and 24h post SCI
(a) 6h         (b) 24h
33
Figure 5. Dexmedetomidine polarises microglial responses
Panel A: left, Panel B: right.
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Legends to figures
Figure 1. Dexmedetomidine (DEX) improves behavioural outcomes 4 weeks 
post-SCI.
Figure 1A. In paw placement test, rats with right C5 injury had less contralateral 
forepaw placement for weight support, which suggests better recovery in ipsilateral 
forelimb, after DEX treatment (SD) over 4-week period, compared to vehicle control 
(SCI) (Figure 1A-1). Between SCI and SD groups, there are significant DEX treatment 
effect [F(1,120)=40.82, p<0.0001] in percentage of contralateral paw placement 
using two-way ANOVA with repeated measures. In a separate group, spinal injured 
rats were pretreated with 2 antagonist, Yoh before DEX administration (SDY), the 
functional benefit of DEX was partially reversed (SD vs SDY, [F(1,96)=13, p=0.0005], 
two-way ANOVA with repeated measures). At the end of 4 weeks post SCI (Figure 1A-
2), we observed significant improvement in SD group, compared to SCI (*** 
p<0.0001, one-way ANOVA with Tukey’s test). Such functional improvement was 
partially reversed by Yoh pretreatment (** p=0.0099, one-way ANOVA with Tukey’s 
test). (n=8-10 in each group).
Figure 1B. In grooming test, rats with right C5 SCI had better grooming scores in right 
upper limb after DEX treatment (SD) over 4-week period, compared to vehicle control 
(SCI) (Figure 1B-1). Between SCI and SD groups, there are significant treatment effect 
[F(1,14)=16.49, p=0.0012] by two way-ANOVA with repeated measures. In a separate
group, spinal injured rats were pretreated with 2 antagonist, Yoh before DEX 
administration, the functional benefit of DEX was partially reversed (SD vs SDY, 
[F(1,14)=4.801, p=0.0459], two-way ANOVA with repeated measures). At the end of 4
weeks post SCI (Figure 1B-2), we observed significant improvement in SD group, 
compared to SCI (** p=0.005, one-way ANOVA with Tukey’s test). The functional 
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improvement was partially reversed by Yoh pretreatment (* p=0.0366, one-way 
ANOVA with Tukey’s test). (n=8-10 in each group).
Figure 2. DEX reduces damage and protects spinal tissue at injury site 
following SCI. 
Figure 2A. DEX reduces maximal injury areas and spares white matter at SCI 
epicentre. Eriochrome Cyanine (EC) staining was used to assess severity of spinal 
tissue injury at the epicentre. The size of lesion volume and spared tissue was 
quantitated at the section with maximal injury. Microscopic images (4X) show 
representative sections in each treatment group (Figure 2A-1, 2A-2, 2A-3). The lesion 
volume was significantly reduced (Figure 2A-4) and more spared total spinal tissue 
(Figure 2A-5), especially white matter was preserved in SD group (Figure 2A-6, * 
p<0.05, one-way ANOVA with Tukey’s test; n=8-10 in each group). Pretreatment of 
2 antagonist (SDY) partially reduced the spared white matter by DEX (Figure 2A-6, * 
p<0.05, one way-ANOVA with Tukey’s test; n=8-10 in each group). Due to large 
within-group variation, DEX had no effect on grey matter sparing (Figure 2A-7). 
Figure 2B. DEX decreases lesion volume from rostral to caudal direction.
Rostro-caudal sections by EC staining were quantitated for lesion size (-960, -720, -
480, -240, 0, 240, 480, 720, 960 m). The sizes of injury areas at the indicated 
distances from the epicentre (distance=0µm) are significantly reduced in SD group, 
compared to SCI (SCI vs SD, p<0.001, two-way ANOVA with multiple comparisons, 
n=8-10 in each group). Pretreatment of 2 antagonist (Yoh) leads to partial reversal 
of DEX effect on tissue protection (SD vs SDY; p<0.001, two-way ANOVA with 
multiple comparisons, n=8-10 in each group).
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Figure 3. Microglia activation is mitigated by DEX at injury site
CD11b positive cells (microglia) in spinal injured rats treated with saline (SCI: A, C, E) 
or DEX (SD: B, D, F). Image C and D are cross sections at SCI epicentre; image A and 
B are sections 480 µm rostral to the epicentre and image E and F are 480 µm caudal. 
Signals of CD11b positive cells are decreased following DEX treatment (SD), 
compared to vehicle control group (SCI). The decrease is statistically significant at 
480 µm both rostrally (Image A vs B) and caudally (Image E vs F) to the injury 
epicentre (G: SCI vs SD * p<0.05 by two-way ANOVA with multiple comparisons, n=6 
in each group). Total count of CD11b positive signals across the five different 
locations suggests significant reduction of activated microglia in SD group (H, * 
p<0.05, Student’s t test, n=6 in each group).
Figure 4. DEX modulates neuroinflammatory response following SCI
Figure 4A. RNA expression of cytokines and markers that are pro-inflammatory was 
assessed at both 6h and 24h following SCI. At 6h (a) and 24h (b), IL-1, TNF and IL-6 
were all elevated after injury (SCI), which were reduced by DEX treatment (SD). The 
elevated expression of CD11b after SCI was also downregulated by DEX (SD). 2-
antagonist (Yoh) was able to reverse the effect of DEX on IL-6, with a trend in others, 
including IL-1, TNF and CD11b (SDY). (* p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001, one-way ANOVA with Tukey’s test, n=4 in each group).
Figure 4B. Expression profile of anti-inflammatory and pro-resolving/reparative “M2” 
genes at 6h and 24h post-SCI. At both 6h (a) and 24h (b), IL-4, Arginase-1 and CD206 
were all enhanced by DEX (SD) post-SCI. However, Yoh significantly reversed DEX 
induced upregulation (SDY) (* p<0.05, ** p<0.01, one-way ANOVA with Tukey’s test, 
n=4 in each group).  
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Figure 5. DEX polarises microglial responses
Gene expression profile of inflammatory cytokines and mediators in the cell lysate of 
cultured microglia. In panel A (left), pro-inflammatory cytokines were all up-regulated 
after LPS treatment for 1h. DEX significantly reduced their expression, while Yoh 
reversed the suppression of IL-6 (* p<0.05, ** p<0.01, **** p<0.0001; one-way 
ANOVA with Tukey’s test; n=6 wells in each group). In panel B (right), expression of 
“M2” response associated genes (IL-4, Arginase-1 and CD206) were also assessed. 
While all were decreased after LPS treatment for 1h, the level of IL-4, Arginase-1 or 
CD206 was significantly enhanced by DEX. Yoh, on the other hand, inhibited DEX’s 
effect on all of them (* p<0.05; ** p<0.01; *** p<0.001; **** p<0.0001; one-way 
ANOVA with Tukey’s test; n=6 wells in each group).
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